Abstract

SO.11.02

GS-101 – Eye-drop treatment in corneal neovascularisation

Salvador Garcia-Delpech, Stephanie Rohrweck, Manuel Díaz-Llopis, David Salom, Patricia Udaondo, Isabel Mayo, Elena Quintana
Oftalmología, Hospital Universitario La Fe, Valencia, Spain

Objective
Angiogenesis is a complex, physiological process regulated by different pro- and anti-angiogenic factors. The antisense oligonucleotide GS-101 targets the IRS-1 messenger RNA (Insulin Receptor Substrate-1) and inhibits its expression in a dose-dependent way. Previous publications demonstrated in vitro, that partial IRS-1 down-regulation interferes with angiogenesis. Purpose: To study the utility of local application of GS-101 in corneal neovascularisation.
Methods
Administration of one drop of GS-101 twice-a-day during three months in five patients with corneal neovascularisation; clinical and photographical controls were performed every ten days.
Results
Corneal neovascularisation was reduced at least 30% in all cases. In two patients almost complete vascular regression was obtained (80% vascular regression).
Conclusions
Our results demonstrate that GS-101, an antisense oligonucleotide that targets gene expression of IRS-1 mRNA, seems to be an effective treatment option for corneal neovascularisation.

Copyright: 2009 Porstmann Kongresse GmbH. All rights reserved. Impressum, Disclaimer.